Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21881215.
- Also identified by DOI 10.1172/JCI57158 and PMC identifier 3163962.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
Medical subject headings
- Cytokine Receptor gp130
- Interleukin-6
- Receptors, Interleukin-6
- Signal Transduction